The overarching goal of the lab is to identify putative predictive genomic biomarkers for targeted therapies and understand primary and secondary resistance mechanisms for these therapies. The lab utilizes next-generation sequencing strategies for the development and analysis of genomics-driven medicine clinical trials (precision medicine) and genetic characterization of therapeutic resistance. The lab also specializes in using high-throughput functional screens to identify therapeutic targets and molecular strategies to advance for pre-clinical modeling in cell lines and patient-derived xenograft models.
Chad Brenner, Ph.D.
Cell and Systems Biology, Genomics/Proteomics, Computational Biology, Cancer Biology